Friday, 11 March 2016 22:43

Anticoagulation news items. Weeks commencing 7th March 2016

Anticoagulation in coronary intervention

European Heart Journal

This review article summarises the current status of anticoagulation for percutaneous coronary intervention and the results of most recent trials and gives recommendations for different clinical scenarios.


Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes


This review article covers the mechanism of action and roles of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes. Treatments covered are aspirin, clopidogrel, ticagrelor, vorapaxar, unfractionated heparin, low-molecular-weight heparins and fondaparinux.


Coagulation Factor IX (recombinant) albumin fusion protein (albutrepenonacog alfa), for haemophila B approved for use in US

US Food and Drug Administration

This has been approved in the US, for use in children and adults, following two trials of patients aged 1-61 years. It was shown to be effective in controlling bleeding episodes and managing perioperative bleeding.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: